Australia-based Proteomics International Laboratories has reported positive results from the validation clinical study of its PromarkerD blood test to predict diabetic kidney disease.
Designed as a predictive diagnostic test, PromarkerD uses a protein fingerprint for measuring kidney disease in diabetic patients. The blood test has the capacity to predict as well as diagnose the disease.
The results from the study showed that the PromarkerD blood test can anticipate the onset of the disease better than the existing measures.
